Legend Biotech Corp ADR (LEGN) Stock Price, Quote & News

Company Profile

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candida...

Industry: Biotechnology

Sector: Healthcare

Phone: 737 317 5050

Website: legendbiotech.com

Address:

2101 Cottontail Lane, Somerset, United States

Ken012 Sep. 13 at 6:10 PM

$LEGN Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $78 to $74.

0 · Reply

Stockseeking Sep. 13 at 1:50 PM

$LEGN Come one, big sharks

0 · Reply

Theflash88 Sep. 11 at 7:49 PM

$LEGN

0 · Reply

Theflash88 Sep. 11 at 7:35 PM

$LEGN Adding at the lows.

0 · Reply

Theflash88 Sep. 11 at 7:34 PM

$LEGN $50+ price targets.

0 · Reply

bullwink Sep. 11 at 6:29 PM

$LEGN What a pathetic state of this stock. Completely fucked my portfolio in the last 2-3 weeks

1 · Reply

KY3000 Sep. 11 at 4:35 PM

$LEGN I’m starting to feel they put Bash in there to fail, benefits a lot of ppl if legend goes under

0 · Reply

KY3000 Sep. 11 at 4:24 PM

$LEGN what’s the use of research? Find stocks 35-100x market cap and get rich

0 · Reply

KY3000 Sep. 11 at 4:20 PM

$LEGN bought some 18.99, immediately drops and pegs. Tutes hunt the poor.

0 · Reply

Valueforall Sep. 11 at 3:44 PM

$LEGN what happens when the dip keeps dipping? You bumpy that mudhaphukking dip!

0 · Reply

Legend Biotech price target lowered to $74 from $78 at Barclays

Sep 10, 2026, 8:00 AM EDT - 3 days ago

Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting

Sep 1, 2026, 8:00 AM EDT - 12 days ago

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

2026-08-17T11:06:17.000Z - 27 days ago

Legend Biotech price target lowered to $24 from $29 at TD Cowen

2026-08-17T10:20:22.000Z - 27 days ago

Legend Biotech price target lowered to $78 from $80 at Barclays

2026-08-17T10:16:57.000Z - 27 days ago

Legend Biotech downgraded to Perform from Outperform at Oppenheimer

2026-08-17T10:14:03.000Z - 27 days ago

Oppenheimer downgrades Legend Biotech to Perform on CEO/competition overhangs

JNJ

2026-08-17T09:36:45.000Z - 27 days ago

Legend Biotech price target raised to $49 from $48 at Morgan Stanley

Aug 11, 2026, 8:00 AM EDT - 4 weeks ago

Legend Biotech Earnings Call Transcript: Q2 2026

Aug 11, 2026, 8:00 AM EDT - 4 weeks ago

Legend Biotech Earnings release: Q2 2026

Aug 11, 2026, 8:00 AM EDT - 4 weeks ago

Legend Biotech Slides: Q2 2026

2026-08-11T11:05:38.000Z - 4 weeks ago

Legend Biotech reports Q2 EPS 16c vs. 3c last year

2026-07-27T16:05:40.000Z - 6 weeks ago

Legend Biotech falls -15.1%

2026-07-27T14:00:11.000Z - 6 weeks ago

Legend Biotech falls -12.5%

2026-07-27T13:01:11.000Z - 6 weeks ago

Legend Biotech price target lowered to $59 from $63 at RBC Capital

2026-07-27T10:05:53.000Z - 6 weeks ago

Legend Biotech CEO Ying Huang steps down, Alan Bash named interim CEO

Jul 27, 2026, 6:00 AM EDT - 6 weeks ago

Legend Biotech Announces CEO Transition

2026-07-24T08:25:10.000Z - 7 weeks ago

Legend Biotech downgraded to Neutral from Buy at UBS

2026-07-13T09:45:05.000Z - 2 months ago

Legend Biotech resumed with a Neutral at JPMorgan

2026-07-07T11:35:49.000Z - 2 months ago

Legend Biotech price target lowered to $63 from $64 at RBC Capital

2026-06-18T16:07:41.000Z - 2 months ago

Legend Biotech falls -14.4%

2026-06-18T14:07:36.000Z - 2 months ago

Legend Biotech falls -12.2%

2026-06-18T02:05:06.000Z - 2 months ago

Legend Biotech 7.7M share Spot Secondary priced at $29.35

Jun 17, 2026, 9:21 PM EDT - 2 months ago

Legend Biotech Corporation Announces Pricing of Public Offering

2026-06-17T21:10:10.000Z - 2 months ago

Legend Biotech secondary offering; price range $29.35-$31.35

Jun 17, 2026, 4:29 PM EDT - 2 months ago

Legend Biotech Corporation Announces Proposed Public Offering

$Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma$

Jun 15, 2026, 8:00 AM EDT - 3 months ago

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Jun 2, 2026, 9:31 AM EDT - 3 months ago

Legend's experimental cell therapy shows promise in blood cancer patients

Jun 2, 2026, 9:30 AM EDT - 3 months ago

Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)

Jun 1, 2026, 10:00 AM EDT - 3 months ago

Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026

May 31, 2026, 7:00 PM EDT - 3 months ago

Legend Biotech Transcript: American Society of Clinical Oncology (ASCO) Annual Meeting 2026

May 21, 2026, 5:00 PM EDT - 3 months ago

Legend Biotech Announces Presentations at ASCO 2026

May 12, 2026, 8:00 AM EDT - 4 months ago

Legend Biotech Earnings Call Transcript: Q1 2026

May 12, 2026, 8:00 AM EDT - 4 months ago

Legend Biotech Earnings release: Q1 2026

May 12, 2026, 8:00 AM EDT - 4 months ago

Legend Biotech Slides: Q1 2026

May 12, 2026, 7:00 AM EDT - 4 months ago

Legend Biotech Reports First Quarter 2026 Results and Recent Highlights

May 4, 2026, 8:00 AM EDT - 4 months ago

Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results

Mar 10, 2026, 8:00 AM EDT - 6 months ago

Legend Biotech Earnings Call Transcript: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 6 months ago

Legend Biotech Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 6 months ago

Legend Biotech Earnings release: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 6 months ago

Legend Biotech Slides: Q4 2025

Mar 10, 2026, 7:00 AM EDT - 6 months ago

Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

Feb 24, 2026, 8:00 AM EST - 6 months ago

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results

Jan 14, 2026, 12:00 PM EST - 8 months ago

Legend Biotech Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 12:00 PM EST - 8 months ago

Legend Biotech Slides: 44th Annual J.P. Morgan Healthcare Conference

Dec 9, 2025, 3:31 PM EST - 9 months ago

Cancer Study Buoys These Small Biotechs

ACLX TERN

Dec 6, 2025, 2:00 PM EST - 9 months ago

Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025

Dec 3, 2025, 7:00 AM EST - 9 months ago

Legend Biotech Slides: Corporate presentation

Nov 13, 2025, 12:08 PM EST - 10 months ago

Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

Nov 12, 2025, 8:00 AM EST - 10 months ago

Legend Biotech Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:00 AM EST - 10 months ago

Legend Biotech Earnings release: Q3 2025

Nov 12, 2025, 8:00 AM EST - 10 months ago

Legend Biotech Slides: Q3 2025

Nov 3, 2025, 11:05 AM EST - 10 months ago

Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Oct 29, 2025, 8:00 AM EDT - 10 months ago

Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results

Oct 10, 2025, 6:36 PM EDT - 11 months ago

US FDA adds boxed warning to J&J, Legend Biotech's cancer therapy

JNJ

Sep 9, 2025, 4:05 PM EDT - 1 year ago

Legend Biotech Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 7:00 AM EDT - 1 year ago

Legend Biotech Slides: Corporate Presentation

Aug 18, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Appoints Carlos Santos as Chief Financial Officer

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Earnings Call Transcript: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Earnings release: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Slides: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights

Jul 1, 2025, 10:00 AM EDT - 1 year ago

Legend Biotech Slides: Corporate Presentation

Jun 4, 2025, 6:10 PM EDT - 1 year ago

Mizuho's Jared Holz details potential biotech, pharma acquisitions

INSM VRNA

Jun 3, 2025, 10:45 AM EDT - 1 year ago

Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting

May 22, 2025, 5:15 PM EDT - 1 year ago

Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT

May 13, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Earnings Call Transcript: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Earnings release: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Slides: Q1 2025

May 13, 2025, 7:00 AM EDT - 1 year ago

Legend Biotech Reports First Quarter 2025 Results and Recent Highlights

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Earnings Call Transcript: Q4 2024

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Annual report: Q4 2024

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Earnings release: Q4 2024

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Legend Biotech Slides: Q4 2024

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights

Jan 14, 2025, 6:45 PM EST - 1 year ago

Legend Biotech Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 6:45 PM EST - 1 year ago

Legend Biotech Slides: FY 2025

Dec 19, 2024, 8:01 AM EST - 1 year ago

Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

$CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma$

Dec 9, 2024, 7:35 PM EST - 1 year ago

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

Dec 8, 2024, 11:00 PM EST - 1 year ago

Legend Biotech Transcript: The 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Legend Biotech Earnings Call Transcript: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Legend Biotech Earnings release: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Legend Biotech Slides: Q3 2024

Nov 7, 2024, 7:30 AM EST - 1 year ago

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 5, 2024, 9:10 AM EST - 1 year ago

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

Nov 4, 2024, 7:30 AM EST - 1 year ago

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

Oct 3, 2024, 7:41 AM EDT - 1 year ago

Legend Biotech to set up new R&D facility in Philadelphia

Oct 3, 2024, 7:30 AM EDT - 1 year ago

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

Sep 27, 2024, 4:35 PM EDT - 1 year ago

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

Sep 24, 2024, 9:00 AM EDT - 1 year ago

Multiply Labs Announces a Collaboration on Automating Cell Therapy Manufacturing with Legend Biotech

Sep 4, 2024, 2:35 PM EDT - 2 years ago

Legend Biotech Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 20, 2024, 8:00 AM EDT - 2 years ago

Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 9, 2024, 8:00 AM EDT - 2 years ago

Legend Biotech Earnings Call Transcript: Q2 2024

Aug 9, 2024, 8:00 AM EDT - 2 years ago

Legend Biotech Earnings release: Q2 2024

Aug 9, 2024, 8:00 AM EDT - 2 years ago

Legend Biotech Slides: Q2 2024

Aug 9, 2024, 7:00 AM EDT - 2 years ago

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

Ken012 Sep. 13 at 6:10 PM

$LEGN Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $78 to $74.

0 · Reply

Stockseeking Sep. 13 at 1:50 PM

$LEGN Come one, big sharks

0 · Reply

Theflash88 Sep. 11 at 7:49 PM

$LEGN

0 · Reply

Theflash88 Sep. 11 at 7:35 PM

$LEGN Adding at the lows.

0 · Reply

Theflash88 Sep. 11 at 7:34 PM

$LEGN $50+ price targets.

0 · Reply

bullwink Sep. 11 at 6:29 PM

$LEGN What a pathetic state of this stock. Completely fucked my portfolio in the last 2-3 weeks

1 · Reply

KY3000 Sep. 11 at 4:35 PM

$LEGN I’m starting to feel they put Bash in there to fail, benefits a lot of ppl if legend goes under

0 · Reply

KY3000 Sep. 11 at 4:24 PM

$LEGN what’s the use of research? Find stocks 35-100x market cap and get rich

0 · Reply

KY3000 Sep. 11 at 4:20 PM

$LEGN bought some 18.99, immediately drops and pegs. Tutes hunt the poor.

0 · Reply

Valueforall Sep. 11 at 3:44 PM

$LEGN what happens when the dip keeps dipping? You bumpy that mudhaphukking dip!

0 · Reply

Stockseeking Sep. 11 at 3:34 PM

$LEGN Just compared to SRRK, a drug waiting for approval and the drug may or may not have a blockbuster potential, has a market cap of 6.7 billion. While, LEGN has a market cap of 3.6 billion!

1 · Reply

KY3000 Sep. 11 at 2:37 PM

$LEGN lol

0 · Reply

Stockseeking Sep. 11 at 11:51 AM

$LEGN I cannot understand why this company has a blockbuster drug with a market cap of less than 4 billion

2 · Reply

KY3000 Sep. 10 at 8:26 PM

$LEGN Committee Will Weigh Biotech Innovation Against Security Risks | Legis1 https://legis1.com/news/biotech-innovation-security-committee-will-weigh

0 · Reply

KY3000 Sep. 10 at 6:54 PM

$LEGN trash

0 · Reply

Merlintrader Sep. 10 at 6:32 PM

Elaborato per 14s Legend Biotech ($LEGN): CARVYKTI Presentations at IMS to Include Five-Year CARTITUDE-2 Follow-Up, Real-World Evidence and Safety — Updated Sep 10 https://www.merlintrader.com/legend-biotech-stock-hub/

0 · Reply

KY3000 Sep. 10 at 2:57 PM

$LEGN fukme

0 · Reply

DiamondHandsBTW Sep. 10 at 2:27 PM

$LEGN stock will continue to decline until a buyout

0 · Reply

BiodegradableBurger Sep. 10 at 2:06 PM

$LEGN There’s only one reason this is doing so badly - a curse was placed on this company.

1 · Reply

KY3000 Sep. 10 at 12:25 AM

$LEGN JJ/Novartis getting spanked in the clinic. Q3 needs to be 800$ mill or better,

0 · Reply

KY3000 Sep. 10 at 12:16 AM

$LEGN Xi/Trump meeting soon, china winning right now

0 · Reply

NVDAMillionaire Sep. 9 at 8:05 PM

$LEGN Excellent article that nails exactly where LEGN stands right now. So if you want to update your LEGN knowledge or get acquainted with LEGN, this is a must read. https://everyticker.com/quote/LEGN/analysis/legend-biotech-s-manufacturing-inflection-from-cash-burn-to-5b-car-t-ambition-nasdaq-legn

0 · Reply

Market Cap	3.61B
Revenue (ttm)	1.03B
Net Income (ttm)	-296.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-28.85%
Debt to Equity Ratio	0.13

Volume	4,279,400
Avg Vol	2,281,594
Day's Range	N/A - N/A
Shares Out	193.77M
Stochastic %K	1%
Beta	0.40
Analysts	Sell
Price Target	$48.48